Agomab Therapeutics NV (AGMB) Liabilities and Shareholders Equity (2024 - 2026)
Agomab Therapeutics (AGMB) posted Liabilities and Shareholders Equity of $338.2 million for Q2 2026, up 89.0% on a QoQ basis from $178.9 million in Q4 2025.
Powered by 
Analysis
Agomab Therapeutics NV (AGMB) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
Agomab Therapeutics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $338.2 million in Q2 2026.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 338.16 Mn |
| Dec 31, 2025 | 178.92 Mn |
| Dec 31, 2024 | 220.51 Mn |
API Access
Agomab Therapeutics NV Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AGMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "AGMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AGMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();